v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Operating expenses:        
Research and development $ 5,718,184 $ 1,817,959 $ 10,644,898 $ 3,306,798
General and administrative 16,608,211 6,160,812 24,463,431 10,539,709
Depreciation and amortization 22,208 9,979 43,223 17,914
Total operating expenses 22,348,603 7,988,750 35,151,552 13,864,421
Loss from operations (22,348,603) (7,988,750) (35,151,552) (13,864,421)
Other income (expense):        
Interest income, net 3,454 39,146 43,030 45,269
Loss on foreign currency translation (1,161) 0 (1,161) 0
Loss before income taxes (22,346,310) (7,949,604) (35,109,683) (13,819,152)
Income taxes (benefit) 0 0 0 0
Net loss (22,346,310) (7,949,604) (35,109,683) (13,819,152)
Non-controlling interest 3,158,025 0 4,585,838 0
Net loss attributable to BioSig Technologies, Inc. (19,188,285) (7,949,604) (30,523,845) (13,819,152)
Preferred stock dividend (4,699) (4,868) (9,317) (15,409)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (19,192,984) $ (7,954,472) $ (30,533,162) $ (13,834,561)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.72) $ (0.38) $ (1.20) $ (0.72)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 26,537,058 20,671,193 25,463,154 19,267,514

Source